Business Context and Reporting Period
Company: Coeptis Therapeutics Holdings, Inc. (trading symbol: COEP). Note: The request metadata referenced "Z Squared Inc.," but the filing text identifies the registrant as Coeptis Therapeutics Holdings, Inc., which entered into a pending merger agreement with Z Squared, Inc. on April 25, 2025.
Reporting Period: Quarterly period ended June 30, 2025 (Form 10-Q).
Business Overview: The Company operates as a holding company with two primary segments: Biotechnology (developing cell therapy platforms for cancer and autoimmune diseases) and Technology (AI-powered marketing software and robotic process automation via the NexGenAI platform). The Company is classified as a Non-accelerated Filer, Smaller Reporting Company, and Emerging Growth Company.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 | As of June 30, 2025 |
|---|---|---|---|
| Total Revenue | $200,681 | $263,555 | - |
| Gross Profit | $155,524 | $173,242 | - |
| Net Loss (Total) | $(4,334,586) | $(7,755,527) | - |
| Net Loss (Attributable to Common Stockholders) | $(3,534,595) | $(6,592,325) | - |
| Loss Per Share (Basic & Diluted) | $(1.17) | $(2.29) | - |
| Cash and Cash Equivalents | - | - | $1,996,726 |
| Marketable Securities | - | - | $990,566 |
| Total Assets | - | - | $12,191,479 |
| Total Liabilities | - | - | $5,111,349 |
| Stockholders' Equity | - | - | $7,080,130 |
| Convertible Notes Payable (Net) | - | - | $1,042,007 |
| Notes Payable (Current, in Default) | - | - | $100,000 |
Material Changes vs. Prior Period
- Revenue Generation: The Company recorded $263,555 in revenue for the six months ended June 30, 2025, compared to $0 for the same period in 2024. This revenue is derived from the Technology segment (NexGenAI platform services).
- Operating Expenses: Total operating expenses increased to $8,751,440 for the six months ended June 30, 2025, from $5,750,485 in the prior year period. The increase was driven primarily by professional services expenses ($5.3M vs. $2.0M) related to the pending Merger Agreement with Z Squared, Inc.
- Net Loss: Net loss increased to $7.76M for the six months ended June 30, 2025, from $6.04M in the prior year period.
- Liquidity: Cash and cash equivalents increased from $532,885 at December 31, 2024, to $1,996,726 at June 30, 2025, largely due to financing activities including a Series A preferred stock offering and proceeds from notes payable.
- Derivative Liabilities: The Company recognized a gain of $798,430 for the six months ended June 30, 2025, due to changes in the fair value of derivative liabilities (warrants and SEPA), compared to a loss of $114,375 in the prior year period.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing states that the Company's accumulated deficit of $105.99M and net losses raise substantial doubt about its ability to continue as a going concern. Management plans to raise additional capital through equity or debt sales.
- Pending Merger: On April 25, 2025, the Company entered into a Merger Agreement to acquire Z Squared, Inc. The transaction involves a spin-out of Coeptis's biotechnology operations prior to the merger. The merger is expected to close in 2025.
- Debt Status: A $100,000 note payable is listed as "in default" as of June 30, 2025. Additionally, the Company has a Standby Equity Purchase Agreement (SEPA) with Yorkville, which includes a convertible note component.
- Subsequent Events:
- July 11, 2025: Commenced a private placement common stock offering ($2.5M - $5.0M).
- July 14, 2025: Yorkville converted $1.14M of principal and interest into 158,582 shares of common stock.
- July 29, 2025: Final 625 shares of Series A preferred stock were converted to common stock.
- Internal Controls: Management concluded that disclosure controls and procedures were effective as of June 30, 2025, following remediation of material weaknesses identified in 2023.
Investor Verification Checklist
- Merger Completion: Verify the status of the pending merger with Z Squared, Inc. and the execution of the biotechnology spin-out.
- Debt Default: Confirm the status of the $100,000 note payable currently in default and any potential acceleration of other debt obligations.
- Liquidity Runway: Assess the sufficiency of the $2.0M cash balance against the $7.8M net loss run rate and upcoming capital requirements for R&D and operations.
- Revenue Sustainability: Evaluate the durability of the Technology segment revenue ($263k for six months) and the concentration risk (three customers accounted for 100% of advertising revenue).
- Equity Dilution: Monitor the impact of the SEPA, convertible notes, and recent private placement on share count and per-share value.